Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

By R. Stupp, M. Hegi, W. Mason, M. J. van den Bent, M. Taphoorn, Robert C. Janzer, S. Ludwin, A. Allgeier, B. Fisher, K. Bélanger and 14 more. The Lancet Oncology, 2009

7,309 citations recorded by the source corpus.

Subfields: Biotechnology, Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/925d73157c731c36e540b2cc12a83a1bf1b61be9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Pulmonary and Respiratory Medicine

Citations in the corpus

Survival in glioblastoma: a review on the impact of treatment modalities (2016, background): “rently, the best that can be offered to these patients, by performing surgical resection plus concurrent chemoradiotherapy, is a modest 14-month median survival [4].”
Epidemiologic and Molecular Prognostic Review of Glioblastoma (2014, methodology): “Additionally, it is associated with better response to TMZ as well as RT and improves progression free survival (PFS) and OS with combined treatment approach (TMZ + RT) than either treatment modality alone (77, 84, 92, 94, 95).”
m6A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells (2017, background): “Even with the combined surgical resection, radiation therapy, and chemotherapy, median survival of patients is less than 15 months after diagnosis (Stupp et al., 2009; Johnson and O'Neill, 2012).”
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “Concomitant and adjuvant TMZ chemotherapy in addition to radiotherapy (TMZ/RT→ TMZ) significantly improved median, 2- and 5-year survival in a large randomised trial, and is the current standard of care for patients with GBM up to age 70 [34, 35] [I, A], or fit elderly patients older than 70 years [”
Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques. (2016, methodology): “All patients were treated according to standard of care, which included maximal safe resection, radiotherapy, and concomitant and adjuvant chemotherapy with temozolomide.(14) All patients were followed from time of surgery (typically 2–3 days after baseline MRI) until death to determine overall surv”
Identifying the Best Machine Learning Algorithms for Brain Tumor Segmentation, Progression Assessment, and Overall Survival Prediction in the BRATS Challenge (2018, background): “The median OS of the described cohorts is not significantly different from the median OS of GBM patients in several randomized Phase III trials, noting that our cohort consists of unselected patients rather than those eligible for such trials [13,14].”
Cancer stem cells in glioblastoma (2015, background): “Additionally, the use of CD133 as a stemmarker is complicated by the observation that expression of CD133 can be regulated at the level of the cell cycle, with potentially slow-cycling NSPCs lacking CD133 expression during G0/G1 cell cycle phase but still maintainingmultipotency (Sun et al. 2009).”
Glioblastoma: Overview of Disease and Treatment (2016, background): “The survival advantage remained because the TMZ plus RT cohort had a higher proportion of long-term survivors than the RT alone group with 27% versus 11% at two years and 10% versus 2% at five years, respectively (Stupp et al., 2009).”